|
US6419927B1
(en)
|
1981-09-08 |
2002-07-16 |
Anthony Cerami |
Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
|
|
US6309640B1
(en)
|
1981-09-08 |
2001-10-30 |
The Rockefeller University |
Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
|
|
US5700466A
(en)
*
|
1981-09-08 |
1997-12-23 |
The Rockefeller University |
Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
|
|
GB2233559B
(en)
*
|
1988-03-11 |
1992-03-04 |
Celltech Ltd |
Antibodies for use in antilymphocyte antibody therapy
|
|
DE3823804A1
(de)
*
|
1988-07-14 |
1990-01-18 |
Basf Ag |
Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten
|
|
NZ229922A
(en)
*
|
1988-07-18 |
1992-04-28 |
Chiron Corp |
Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions
|
|
EP0355067A1
(en)
*
|
1988-08-19 |
1990-02-21 |
Celltech Limited |
Pharmaceutical products for anti-neoplastic therapy
|
|
DE10399036I1
(de)
*
|
1989-08-07 |
2004-04-01 |
Peptide Technology Ltd |
Bindeligande für Tumornekrosisfaktor.
|
|
US20030225254A1
(en)
*
|
1989-08-07 |
2003-12-04 |
Rathjen Deborah Ann |
Tumour necrosis factor binding ligands
|
|
US5959087A
(en)
*
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
|
US5843693A
(en)
*
|
1989-08-16 |
1998-12-01 |
Chiron Corporation |
Assay method for screening for inhibitors of proTNF conversion
|
|
US5998378A
(en)
*
|
1989-08-16 |
1999-12-07 |
Chiron Corporation |
Compositions for the inhibition of TNF hormone formation and uses thereof
|
|
US6586222B1
(en)
|
1989-08-16 |
2003-07-01 |
Chiron Corporation |
Recombinant PR-3 and compositions thereof
|
|
DE69033457T2
(de)
*
|
1989-08-16 |
2000-09-14 |
Chiron Corp |
Prohormonspaltungsplatzblockierungsantikörper
|
|
GB8921123D0
(en)
*
|
1989-09-19 |
1989-11-08 |
Millar Ann B |
Treatment of ards
|
|
US6713610B1
(en)
*
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
US7192584B2
(en)
*
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
US6284471B1
(en)
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
|
US20040120952A1
(en)
*
|
2000-08-07 |
2004-06-24 |
Centocor, Inc |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
US6277969B1
(en)
*
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
DE07006112T1
(de)
*
|
1991-03-18 |
2010-01-21 |
New York University |
Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
|
|
US5919452A
(en)
*
|
1991-03-18 |
1999-07-06 |
New York University |
Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
|
|
ES2121907T3
(es)
*
|
1992-08-28 |
1998-12-16 |
Bayer Ag |
Uso de anticuerpos monoclonales anti-tnf para el tratamiento de meningitis bacterianas.
|
|
US20050260201A1
(en)
*
|
1993-01-29 |
2005-11-24 |
Centocor, Inc. |
Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
|
|
US5888511A
(en)
*
|
1993-02-26 |
1999-03-30 |
Advanced Biotherapy Concepts, Inc. |
Treatment of autoimmune diseases, including AIDS
|
|
US5626843A
(en)
*
|
1993-02-26 |
1997-05-06 |
Advanced Biotherapy Concepts, Inc. |
Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor
|
|
DE4409513C1
(de)
*
|
1994-02-07 |
1995-10-19 |
Knoll Ag |
Verwendung von anti-TNF-Antikörpern als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
|
|
NZ278607A
(en)
*
|
1994-02-07 |
1999-05-28 |
Knoll Ag |
Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
|
|
WO1995024501A1
(en)
|
1994-03-07 |
1995-09-14 |
Cetus Oncology Corporation |
Compositions for the inhibition of tnf formation and uses thereof
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
SI9720020B
(en)
|
1996-02-09 |
2001-12-31 |
Basf Ag |
Human antibodies that bind human TNF alpha
|
|
US7608262B2
(en)
*
|
1996-02-16 |
2009-10-27 |
The Kennedy Institute Of Rheumatology |
Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
|
|
EP1500329B1
(en)
*
|
1996-12-03 |
2012-03-21 |
Amgen Fremont Inc. |
Human antibodies that specifically bind human TNF alpha
|
|
US20020031513A1
(en)
*
|
1997-11-24 |
2002-03-14 |
Shamir Leibovitz |
Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
|
|
CA2364026C
(en)
*
|
1999-03-02 |
2012-08-21 |
Centocor, Inc. |
Anti-tnf.alpha. antibodies in therapy of asthma
|
|
AU771015B2
(en)
*
|
1999-03-18 |
2004-03-11 |
Celgene Corporation |
Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
|
|
JP2003511355A
(ja)
*
|
1999-10-06 |
2003-03-25 |
ビーエーエスエフ アクチェンゲゼルシャフト |
併用療法のためのエンドセリンシグナル伝達経路のインヒビターおよびαｖβ３受容体アンタゴニスト
|
|
US20110195063A1
(en)
*
|
2000-08-07 |
2011-08-11 |
Centocor, Inc. |
Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
|
|
US20050249735A1
(en)
*
|
2000-08-07 |
2005-11-10 |
Centocor, Inc. |
Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
US20060018907A1
(en)
*
|
2000-08-07 |
2006-01-26 |
Centocor, Inc. |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
US20090081234A1
(en)
*
|
2000-08-07 |
2009-03-26 |
George Heavner |
Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions
|
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
|
NZ528076A
(en)
*
|
2001-03-02 |
2005-09-30 |
Medimmune Inc |
Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
|
|
CA2868614A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
TWI327597B
(en)
*
|
2001-08-01 |
2010-07-21 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
|
EP1499352A4
(en)
|
2002-04-12 |
2006-10-11 |
Medimmune Inc |
ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
|
|
US20040009172A1
(en)
*
|
2002-04-26 |
2004-01-15 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
|
AU2003280130B2
(en)
|
2002-06-28 |
2009-06-11 |
Centocor, Inc. |
Mammalian CH1 deleted mimetibodies, compositions, methods and uses
|
|
NZ555692A
(en)
|
2002-07-19 |
2009-02-28 |
Abbott Biotech Ltd |
Treatment of TNF alpha related disorders
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
ES2347239T3
(es)
|
2002-12-02 |
2010-10-27 |
Amgen Fremont Inc. |
Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
|
|
US7101978B2
(en)
*
|
2003-01-08 |
2006-09-05 |
Applied Molecular Evolution |
TNF-α binding molecules
|
|
KR20120035234A
(ko)
|
2003-04-11 |
2012-04-13 |
메디뮨 엘엘씨 |
재조합 ｉｌ?９ 항체 및 그의 용도
|
|
EP2286804A1
(en)
|
2003-05-13 |
2011-02-23 |
DePuy Spine, Inc. |
A method of treating degenerative disc disease
|
|
US7429378B2
(en)
*
|
2003-05-13 |
2008-09-30 |
Depuy Spine, Inc. |
Transdiscal administration of high affinity anti-MMP inhibitors
|
|
US7553827B2
(en)
*
|
2003-08-13 |
2009-06-30 |
Depuy Spine, Inc. |
Transdiscal administration of cycline compounds
|
|
US8273347B2
(en)
|
2003-05-13 |
2012-09-25 |
Depuy Spine, Inc. |
Autologous treatment of degenerated disc with cells
|
|
US7344716B2
(en)
*
|
2003-05-13 |
2008-03-18 |
Depuy Spine, Inc. |
Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
|
|
US20040229878A1
(en)
*
|
2003-05-13 |
2004-11-18 |
Depuy Spine, Inc. |
Transdiscal administration of specific inhibitors of P38 kinase
|
|
US8361467B2
(en)
*
|
2003-07-30 |
2013-01-29 |
Depuy Spine, Inc. |
Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
|
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
|
US8895540B2
(en)
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
|
US7435799B2
(en)
*
|
2004-01-08 |
2008-10-14 |
Applied Molecular Evolution |
TNF-α binding molecules
|
|
CA2563379A1
(en)
*
|
2004-03-31 |
2005-10-20 |
Centocor, Inc. |
Human glp-1 mimetibodies, compositions, methods and uses
|
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療ＴＮＦα相關失調症之多重可變劑量療法
|
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
|
US7393662B2
(en)
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
|
EP1807111A4
(en)
*
|
2004-10-08 |
2009-05-27 |
Abbott Biotech Ltd |
SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
|
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
|
CN101500607B
(zh)
|
2005-05-16 |
2013-11-27 |
阿布维生物技术有限公司 |
TNFα抑制剂治疗腐蚀性多关节炎的用途
|
|
TR201902033T4
(tr)
|
2005-06-30 |
2019-03-21 |
Janssen Biotech Inc |
Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları.
|
|
EP1915620B1
(en)
*
|
2005-08-02 |
2010-06-02 |
Xbiotech Inc |
DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1alpha AUTOANTIBODIES
|
|
US20070041905A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
|
WO2007025977A2
(en)
|
2005-08-30 |
2007-03-08 |
Actogenix Nv |
Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
|
|
TW201337266A
(zh)
|
2005-11-01 |
2013-09-16 |
Abbott Biotech Ltd |
利用生物標記診斷關節黏連脊椎炎之方法及組合物
|
|
MX2008008621A
(es)
|
2005-12-29 |
2008-11-27 |
Centocor Inc |
Anticuerpos anti-il-23 humanos, composiciones, metodos y usos.
|
|
SG170837A1
(en)
|
2006-04-05 |
2011-05-30 |
Abbott Biotech Ltd |
Antibody purification
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
EP2666478A3
(en)
|
2006-04-10 |
2014-10-22 |
AbbVie Biotechnology Ltd |
Uses and compositions for treatment of psoriasis
|
|
US9399061B2
(en)
*
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
|
US20080118496A1
(en)
*
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
US9624295B2
(en)
|
2006-04-10 |
2017-04-18 |
Abbvie Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
|
US20090317399A1
(en)
*
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
|
US20080131374A1
(en)
*
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
|
US20110008282A1
(en)
*
|
2006-05-15 |
2011-01-13 |
Xbiotech, Inc. |
IL-1alpha immunization induces autoantibodies protective against atherosclerosis
|
|
SI2109623T1
(sl)
*
|
2006-05-22 |
2012-05-31 |
Xbiotech Inc |
Zdravljenje raka z anti il protitelesi
|
|
TWI527603B
(zh)
|
2006-06-30 |
2016-04-01 |
艾伯維生物技術有限責任公司 |
自動注射裝置
|
|
US8637469B2
(en)
|
2006-07-11 |
2014-01-28 |
Roy C. Levitt |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
|
US20080014285A1
(en)
*
|
2006-07-13 |
2008-01-17 |
Di Mauro Thomas M |
Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
|
|
DK2068889T3
(da)
|
2006-08-10 |
2020-02-03 |
Roy C Levitt |
Anakinra til anvendelse i behandling af bronchiolitis obliterans syndrom
|
|
MX2009004351A
(es)
|
2006-10-27 |
2009-05-12 |
Abbott Biotech Ltd |
Anticuerpos anti-htnfalfa cristalinos.
|
|
NZ580379A
(en)
|
2007-03-29 |
2012-10-26 |
Abbott Lab |
Crystalline anti-human il-12 antibodies
|
|
EP2703011A3
(en)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
|
SG183709A1
(en)
*
|
2007-08-08 |
2012-09-27 |
Abbott Lab |
Compositions and methods for crystallizing antibodies
|
|
US20090038182A1
(en)
*
|
2007-08-09 |
2009-02-12 |
Lans Maris J |
Footwear with built-in scale
|
|
US20090162351A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Depuy Spine, Inc. |
Transdiscal administration of inhibitors of p38 MAP kinase
|
|
US8986696B2
(en)
*
|
2007-12-21 |
2015-03-24 |
Depuy Mitek, Inc. |
Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
|
|
EP2799450A1
(en)
|
2007-12-31 |
2014-11-05 |
Bayer Intellectual Property GmbH |
Antibodies to TNFalpha
|
|
SG2013054218A
(en)
*
|
2008-01-15 |
2014-10-30 |
Abbott Gmbh & Co Kg |
Powdered protein compositions and methods of making same
|
|
RU2498998C2
(ru)
*
|
2008-05-30 |
2013-11-20 |
ИксБиотеч, Инк. |
АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ
|
|
JP5976319B2
(ja)
*
|
2008-09-12 |
2016-08-23 |
エックスバイオテク，インコーポレイテッドＸｂｉｏｔｅｃｈ，Ｉｎｃ． |
病原性単球の標的化
|
|
US8415291B2
(en)
*
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
|
US20110293605A1
(en)
|
2008-11-12 |
2011-12-01 |
Hasige Sathish |
Antibody formulation
|
|
TWI583418B
(zh)
|
2009-04-29 |
2017-05-21 |
艾伯維生物技術有限責任公司 |
針筒柱塞及自動注射裝置
|
|
RU2571489C2
(ru)
|
2009-10-26 |
2015-12-20 |
Нестек С.А. |
Способы выявления препаратов и аутоантител против tnf
|
|
TWI619521B
(zh)
|
2009-12-15 |
2018-04-01 |
艾伯維生物技術有限責任公司 |
自動注射裝置、自動注射方法及防止不發射情況之方法
|
|
JP5947727B2
(ja)
|
2010-01-20 |
2016-07-06 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
|
|
EP2525813B1
(en)
|
2010-01-20 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
|
KR102167261B1
(ko)
|
2010-06-18 |
2020-10-20 |
엑스바이오테크, 인크. |
관절염 치료
|
|
EP2608808B1
(en)
|
2010-08-23 |
2017-01-18 |
XBiotech, Inc |
Treatment for neoplastic diseases
|
|
BR112013009376A2
(pt)
|
2010-10-18 |
2016-07-26 |
Nestec Sa |
métodos para determinar isótipos de anticorpos antifármacos
|
|
AR084210A1
(es)
*
|
2010-12-08 |
2013-05-02 |
Abbott Lab |
PROTEINAS DE UNION AL TNF-a
|
|
KR101989342B1
(ko)
|
2011-01-24 |
2019-06-14 |
애브비 바이오테크놀로지 리미티드 |
주사기로부터 니들 실드의 제거 및 자동 주사 디바이스들
|
|
PE20141436A1
(es)
|
2011-01-24 |
2014-11-15 |
Abbvie Biotechnology Ltd |
Dispositivos de inyeccion automatica con superficies de agarre sobremoldeadas
|
|
BR112013020981A2
(pt)
|
2011-02-17 |
2016-10-11 |
Nestec Sa |
ensaios para a detecção de auto-anticorpos para os fármacos anti-tnf<244>
|
|
US8658171B2
(en)
|
2011-02-28 |
2014-02-25 |
Livzon Mabpharm Inc. |
Humanized anti-TNFα antibodies
|
|
CN102675460B
(zh)
|
2011-02-28 |
2015-08-19 |
珠海市丽珠单抗生物技术有限公司 |
抗肿瘤坏死因子α的人源化抗体
|
|
US9724409B2
(en)
|
2011-04-01 |
2017-08-08 |
Xbiotech, Inc. |
Treatment of inflammatory skin disease
|
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
MX343324B
(es)
|
2011-07-06 |
2016-11-01 |
Nestec Sa |
Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
|
|
PT2750709T
(pt)
|
2011-09-23 |
2018-11-22 |
Xbiotech Inc |
Tratamento da caquexia
|
|
KR20140084253A
(ko)
|
2011-10-24 |
2014-07-04 |
애브비 인코포레이티드 |
Ｔｎｆ에 대한 면역결합제
|
|
MX2014004980A
(es)
*
|
2011-10-24 |
2014-09-11 |
Abbvie Inc |
Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17.
|
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
|
KR20150043523A
(ko)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
단백질 불균일성의 제어 방법
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
US9545441B2
(en)
|
2012-09-18 |
2017-01-17 |
Xbiotech, Inc. |
Treatment of diabetes
|
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
WO2014151901A1
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Improvement of mammalian cell culture performance through surfactant supplementation of feed media
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
WO2014158231A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
CA2899449A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
|
CA2907140A1
(en)
|
2013-03-15 |
2014-09-25 |
Janssen Biotech, Inc. |
Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
|
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
EP3145951A1
(en)
|
2014-06-24 |
2017-03-29 |
InSight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
|
WO2016004197A1
(en)
|
2014-07-03 |
2016-01-07 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
|
WO2016007764A1
(en)
|
2014-07-09 |
2016-01-14 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
|
|
BR112017011545A2
(pt)
|
2014-12-05 |
2018-03-13 |
Nestec Sa |
ensaio de desvio de mobilidade homogênea indireto para a detecção de produtos biológicos nas amostras do paciente
|
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
|
CN110234351A
(zh)
|
2017-01-30 |
2019-09-13 |
詹森生物科技公司 |
用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
|
|
CN110418652A
(zh)
|
2017-02-07 |
2019-11-05 |
詹森生物科技公司 |
用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
|
|
EP3582813A4
(en)
|
2017-02-16 |
2020-12-30 |
XBiotech, Inc |
TREATMENT OF SUPPURATIVE HIDRADENITIS
|
|
JP2022518208A
(ja)
|
2019-01-15 |
2022-03-14 |
ヤンセン バイオテツク，インコーポレーテツド |
若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
|
|
WO2020152544A1
(en)
|
2019-01-23 |
2020-07-30 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
|
|
CA3133388A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
|
MA55283A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de production de compositions d'anticorps anti-tnf
|
|
KR20210142002A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생성하기 위한 제조 방법
|
|
US11780911B2
(en)
|
2019-05-23 |
2023-10-10 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
|
CN113939531A
(zh)
|
2019-06-03 |
2022-01-14 |
詹森生物科技公司 |
用于治疗银屑病关节炎的抗tnf抗体组合物和方法
|
|
MX2021014882A
(es)
|
2019-06-03 |
2022-03-25 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
|
|
EP3990922A1
(en)
|
2019-06-25 |
2022-05-04 |
ProciseDx Inc. |
Detection of anti-tnf alpha drug biologics and anti-drug antibodies
|
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
|
JP2023551542A
(ja)
|
2020-11-30 |
2023-12-08 |
エニグマ バイオインテリジェンス，インコーポレイテッド |
アルツハイマー病の非侵襲的評価
|
|
EP4261222A1
(en)
|
2020-12-09 |
2023-10-18 |
HK inno.N Corporation |
ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFalpha BISPECIFIC ANTIBODY, AND USES THEREOF
|
|
WO2023281462A1
(en)
|
2021-07-09 |
2023-01-12 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
|
CN117957251A
(zh)
|
2021-07-09 |
2024-04-30 |
詹森生物科技公司 |
用于制备抗tnf抗体组合物的制造方法
|